MNG1017
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.492
- PROTEIN_SECRETION+0.472
- ADIPOGENESIS+0.362
- MYC_TARGETS_V1+0.337
- MTORC1_SIGNALING+0.328
- CHOLESTEROL_HOMEOSTASIS+0.320
- NOTCH_SIGNALING+0.311
- MYC_TARGETS_V2+0.296
- MITOTIC_SPINDLE+0.284
- G2M_CHECKPOINT+0.268
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.386
- INTERFERON_GAMMA_RESPONSE-0.378
- ALLOGRAFT_REJECTION-0.271
- IL6_JAK_STAT3_SIGNALING-0.250
- TNFA_SIGNALING_VIA_NFKB-0.227
- INFLAMMATORY_RESPONSE-0.208
- SPERMATOGENESIS-0.185
- KRAS_SIGNALING_DN-0.180
- COAGULATION-0.109
- MYOGENESIS-0.099
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG458 | — | — | 0.849 |
| 2 | MNG93 | — | — | 0.835 |
| 3 | MNG434 | — | — | 0.826 |
| 4 | MNG1041 | — | — | 0.822 |
| 5 | MNG169 | — | — | 0.820 |
| 6 | TCGA-BH-A1EN-01A-11R-A13Q-07 | — | C | 0.806 |
| 7 | MNG432 | — | — | 0.804 |
| 8 | SRR5903549 | — | cohortA4 | 0.802 |
| 9 | MNG1011 | — | — | 0.800 |
| 10 | R205 | — | — | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.492 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.472 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.362 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.337 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.328 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.311 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.296 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.284 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.268 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.257 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.243 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.226 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.191 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.187 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.173 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.149 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.147 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.145 | Temsirolimus | — uncovered |